Protective effect of a novel Rho kinase inhibitor WAR-5 in experimental autoimmune encephalomyelitis by modulating inflammatory response and neurotrophic factors

Experimental and Molecular Pathology

Volumn 99, Issue 2, 2015, Pages 220-228

  Li, Yan hua ^a   Yu, Jie zhong ^a   Xin, Yan le ^a   Feng, Ling ^a   Chai, Zhi ^b   Liu, Jian chun ^b   Zhang, Hong zhen ^b   Zhang, Guang Xian ^d   Xiao, Bao guo ^a,c   Ma, Cun gen ^a,b  

^a SHANXI DATONG UNIVERSITY   (China)

^b SHANXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c FUDAN UNIVERSITY   (China)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Experimental autoimmune encephalomyelitis; NF B signaling; Rho kinase; Y 27632 derivatives

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ARGINASE 1; BRAIN DERIVED NEUROTROPHIC FACTOR; FASUDIL; GALACTOSYLCERAMIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; NEUROTROPHIN 3; PROTEIN NOGO; RHO KINASE; RHO KINASE INHIBITOR; ROCK II PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WAR 5; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; AMIDE; AMINOPYRIDINE DERIVATIVE; CYTOKINE; NERVE GROWTH FACTOR; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; WAR-5 COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOMODULATION; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOCOMOTION; LYMPHOCYTE COUNT; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TH1 CELL; TH17 CELL; TOXICITY TESTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; MICROGLIA; PATHOLOGY;

MUS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMIDES; AMINOPYRIDINES; ANIMALS; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICROGLIA; NERVE GROWTH FACTORS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RHO-ASSOCIATED KINASES; T-LYMPHOCYTES, REGULATORY;

EID: 84937937293     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.06.016     Document Type: Article

References (53)

1. Aharoni R., Eilam R., Domev H., Labunskay G., Sela M., Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:19045-19050.
2. Alabed Y.Z., Grados-Munro E., Ferraro G.B., Hsieh S.H., Fournier A.E. Neuronal responses to myelin are mediated by rho kinase. J. Neurochem. 2006, 96(6):1616-1625.
3. Barres B.A., Schmid R., Sendnter M., RaffM.C. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 1993, 118:283-295.
4. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
5. Bongiorno D., Petratos S. Molecular regulation of Nogo-A in neural cells: novel insights into structure and function. Int. J. Biochem. Cell Biol. 2010, 42:1072-1075.
6. Cafferty W.B., Duffy P., Huebner E., Strittmatter S.M. MAG and OMgp synergize with Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma. J. Neurosci. 2010, 30:6825-6837.
7. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 2003, 4:299-309.
8. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351:95-105.
9. Dergham P., Ellezam B., Essagian C., Avedissian H., Lubell W.D., McKerracher L. Rho signaling pathway targeted to promote spinal cord repair. J. Neurosci. 2002, 22:6570-6577.
10. Deyts C., Galan-Rodriguez B., Martin E., Bouveyron N., Roze E., Charvin D., Caboche J., Bétuing S. Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS One 2009, 4:e8287.
11. Dubreuil C.I., Winton M.J., McKerracher L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell Biol. 2003, 162:233-243.
12. Elkabes S., DiCicco-Bloom E.M., Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J. Neurosci. 1996, 16:2508-2521.
13. Forgione N., Fehlings M.G. Rho-ROCK inhibition in the treatment of spinal cord injury. World Neurosurg. 2014, 82(3-4):e535-e539.
14. Goodin D.S. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008, 71:S8-S13.
15. Goodin D.S., Frohman E.M., Garmany G.P., Halper J., Likosky W.H., Lublin F.D., Silberberg D.H., Stuart W.H., van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58(2):169-178.
16. Hou S.W., Liu C.Y., LiYH Yu. J.Z., Feng L., Liu Y.T., Guo M.F., Xie Y., Meng J., Zhang H.F., Xiao B.G., Ma C.G. Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect. CNS Neurosci. Ther. 2012, 18:909-917.
17. Ishida T., Takanashi Y., Kiwada H. Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biol. Pharm. Bull. 2006, 29:397-402.
18. Ishizaki T., Uehata M., Tamechika I., Keel J., Nonomura K., Maekawa M., Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 2000, 57:976-983.
19. Julian L., Olson M.F. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases 2014, 5:e29846.
20. Ka M.B., Daumas A., Textoris J., Mege J.L. Phenotypic diversity and emerging new tools to study macrophage activation in bacterial infectious diseases. Front. Immunol. 2014, 5:500.
21. Kalcheim C., Carmeli C., Rosenthal A. Neurotrophin 3 is a mitogen for cultured neural crest cells. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:1661-1665.
22. Koch J.C., Tönges L., Barski E., Michel U., Bähr M., Lingor P. ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS. Cell Death Dis. 2014, 5:e1225.
23. Kutzelnigg A., Lassmann H. Pathology of multiple sclerosis and related inflammatory demyelinating diseases. Handb. Clin. Neurol. 2014, 122:15-58.
24. Lee J.Y., Petratos S. Multiple sclerosis: does Nogo play a role?. Neuroscientist 2013, 19:394-408.
25. Lee J.K., Kim J.E., Sivula M., Strittmatter S.M. Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J. Neurosci. 2004, 24:6209-6217.
26. Lehmann M., Fournier A., Selles-Navarro I., Dergham P., Sebok A., Leclerc N., Tigyi G., McKerracher L. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J. Neurosci. 1999, 19:7537-7547.
27. Li S.N., Wang W., Fu S.P., Wang J.F., Liu H.M., Xie S.S., Liu B.R., Li Y., Lv Q.K., Li Z.Q., Xue W.J., Huang B.X., Chen W., Liu J.X. IL-21 modulates release of proinflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Mediat. Inflamm. 2013, 2013:548073.
28. Li Y.H., Yu J.Z., Liu C.Y., Zhang H., Zhang H.F., Yang W.F., Li J.L., Feng Q.J., Feng L., Zhang G.X., Xiao B.G., Ma C.G. Intranasal delivery of FSD-C10, a novel Rho kinase inhibitor, exhibits therapeutic potential in experimental autoimmune encephalomyelitis. Immunology 2014, 143(2):219-229.
29. Liao J.K., Seto M., Noma K. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 2007, 50(1):17-24.
30. Liu C.Y., Li Y.H., Yu J.Z., Feng L., Hou S.W., Liu Y., Guo M.F., Xie Y., Meng J., Zhang H.F., Xiao B.G., Ma C.G. Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with Fasudil. PLoS One 2013, 8:e54841.
31. LoGrasso P.V., Feng Y. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr. Top. Med. Chem. 2009, 9(8):704-723.
32. Lord F.S., Yang F., Diep Q., Dergham P., Munzer S., Tremblay P., McKerracher L. Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J. Neurotrauma 2008, 25:1309-1322.
33. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
34. McTigue D.M., Horner P.J., Stokes B.T., Gage F.H. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J. Neurosci. 1998, 18:5354-5365.
35. Megan M.V., Tsuneya I. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch. Immunol. Ther. Exp. (Warsz) 2012, 60(4):251-266.
36. Mueller B.K., Mack H., Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 2005, 4(5):387-398.
37. Nakajima K., Honda S., Tohyama Y., Imai Y., Kohsaka S., Kurihara T. Neurotrophin secretion from cultured microglia. J. Neurosci. Res. 2001, 65:322-331.
38. Paintlia A.S., Paintlia M.K., Singh A.K., Singh I. Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-α-dependent mechanism. Glia 2013, 61(9):1500-1517.
39. Pandit L., Murthy J.M. Treatment of multiple sclerosis. Ann. Indian Acad. Neurol. 2011, 14(Suppl. 1):S65-S69.
40. Pedraza C.E., Taylor C., Pereira A., Seng M., Tham C.S., Izrael M., Webb M. Induction of oligodendrocyte differentiation and in vitro myelination by inhibition of rho-associated kinase. ASN Neuro 2014, 6(4).
41. Pernet V., Schwab M.E. The role of Nogo-A in axonal plasticity, regrowth and repair. Cell Tissue Res. 2012, 349:97-104.
42. Saal K.A., Koch J.C., Tatenhorst L., Szegő E.M., Ribas V.T., Michel U., Bähr M., Tönges L., Lingor P. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo. Neurobiol. Dis. 2015, 73:150-162.
43. Sasaki Y., Suzuki M., Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 2002, 93:225-232.
44. Sekimoto M., Tsuji T., Matsuzaki J., Chamoto K., Koda T., Nemoto K., Degawa M., Nishimura S., Nishimura T. Functional expression of the TrkC gene, encoding a high affinity receptor for NT-3, in antigen-specific T helper type 2 (Th2) cells. Immunol. Lett. 2003, 88(3):221-226.
45. Sun X., Minohara M., Kikuchi H., Ishizu T., Tanaka M., Piao H., Osoegawa M., Ohyagi Y., Shimokawa H., Kira J. The selective Rho kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2006, 180:126-134.
46. Surma M., Wei L., Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Futur. Cardiol. 2011, 7:657-671.
47. Suzuki K., Suzuki Y. Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase. Proc. Natl. Acad. Sci. U. S. A. 1970, 66:302-309.
48. Tan H.B., Zhong Y.S., Cheng Y., Shen X. Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage. Int. J. Ophthalmol. 2011, 4(6):652-657.
49. Thöne J., Ellrichmann G., Seubert S., Peruga I., Lee D.H., Conrad R., Hayardeny L., Comi G., Wiese S., Linker R.A., Gold R. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol. 2012, 180:267-274.
50. Wiessner C., Bareyre F.M., Allegrini P.R., Mir A.K., Frentzel S., Zurini M., Schnell L., Oertle T., Schwab M.E. Anti-Nogo-A antibody infusion 24hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. J. Cereb. Blood Flow Metab. 2003, 23:154-165.
51. Yan J., Greer J.M. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol. Disord. Drug Targets 2008, 7:536-557.
52. Yu J.Z., Ding J., Ma C.G., Sun C.H., Sun Y.F., Lu C.Z., Xiao B.G. Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor. J. Neurosci. Res. 2010, 88(8):1664-1672.
53. Zhao Y.F., Zhang X., Ding Z.B., Yang X.W., Zhang H., Yu J.Z., Li Y.H., Liu C.Y., Zhang Q., Zhang H.Z., Ma C.G., Xiao B.G. The therapeutic potential of Rho kinase inhibitor Fasudil derivative FaD-1 in experimental autoimmune encephalomyelitis. J. Mol. Neurosci. 2015, 55(3):725-732.